An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ...

Please provide your email address to receive an email when new articles are posted on . Patients who received rilzabrutinib had a statistically significant durable platelet response vs. placebo.

Please provide your email address to receive an email when new articles are posted on . Most treated patients had two consecutive platelet counts of at least 50 × 10 9 /L within 8 weeks of the first ...

What Is Wayrilz, and Why Does It Matter? Wayrilz (rilzabrutinib) is a new oral medicine for adults with persistent (lasting 3-12 months) or chronic (lasting more than 12 months) immune ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for rilzabrutinib (Wayrilz, Sanofi) to treat immune thrombocytopenia (ITP) in adults who are refractory to other ...

SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...

Doptelet is approved for pediatric thrombocytopenia, offering a new sprinkle formulation for children under six years old. The AVA-PED-301 study showed 27.8% achieved durable platelet response, with ...

An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that isolated thrombocytopenia with mucosal bleeding and petechiae is highly ...

David Kuter, MD, DPhil discusses Wayrilz™ (rilzabrutinib), a new FDA-approved treatment for persistent or chronic immune thrombocytopenia (ITP). Dr Kuter is the Director of Clinical Hematology at ...

(RTTNews) - Sanofi (SNY), Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously ...